Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Recruiting · NCT07486713 · Registry updated 2026-08-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, acute myeloid leukemia, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, glioma, hematologic disorder, leukemia, myeloid leukemia, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 4 | 2026-08-11 | NCT07486713 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rigel Pharmaceuticals | 13 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| New York Presbyterian Hospital-Columbia University Medical Center | New York | United States | 7 |
| UCI Irvine Health | Orange | United States | 1 |